Clinical Trials Logo

Uterine Carcinosarcoma clinical trials

View clinical trials related to Uterine Carcinosarcoma.

Filter by:

NCT ID: NCT05902988 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Start date: October 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

NCT ID: NCT05619913 Recruiting - Clinical trials for Uterine Carcinosarcoma

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

EPOCH
Start date: May 22, 2023
Phase: Phase 2
Study type: Interventional

The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.

NCT ID: NCT05229601 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Start date: April 20, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer they have.

NCT ID: NCT05147558 Recruiting - Clinical trials for Uterine Carcinosarcoma

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

Start date: December 23, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition

NCT ID: NCT04802876 Recruiting - Clinical trials for Hepatocellular Carcinoma

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

ACROPOLI
Start date: April 12, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.

NCT ID: NCT03902379 Withdrawn - Clinical trials for Endometrial Carcinoma

Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer

Start date: July 27, 2016
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer. Web-based intervention, such as coping and communication skills intervention, may help doctors to get a better understanding of ways to help gynecological cancer patients cope with their cancer experience.

NCT ID: NCT03694262 Completed - Endometrial Cancer Clinical Trials

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

EndoBARR
Start date: July 19, 2019
Phase: Phase 2
Study type: Interventional

To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.

NCT ID: NCT01367301 Terminated - Clinical trials for Uterine Carcinosarcoma

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Start date: July 8, 2011
Phase: N/A
Study type: Interventional

This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.

NCT ID: NCT01247571 Completed - Clinical trials for Uterine Carcinosarcoma

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: January 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with uterine cancer that has come back or has not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of uterine cancer by blocking blood flow to the tumor.

NCT ID: NCT01168232 Completed - Clinical trials for Uterine Carcinosarcoma

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: September 7, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well ixabepilone works in treating patients with persistent or recurrent uterine cancer. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.